Baillie Gifford & Co
BCRX icon

Baillie Gifford & Co’s BioCryst Pharmaceuticals BCRX Stock Holding History

Baillie Gifford & Co’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,687
Closed -$14.1K – 312
2023
Q1 		$14.1K Hold
1,687
– – ﹤0.01% 372
2022
Q4 		$19.4K Hold
1,687
– – ﹤0.01% 351
2022
Q3 		$21K Hold
1,687
– – ﹤0.01% 324
2022
Q2 		$18K Hold
1,687
– – ﹤0.01% 349
2022
Q1 		$27K Buy
1,687
+187
+12% +$3K ﹤0.01% 328
2021
Q4 		$21K Hold
1,500
– – ﹤0.01% 369
2021
Q3 		$22K Buy
+1,500
New +$23.7K ﹤0.01% 356

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Baillie Gifford & Co's BCRX Position: Q2 2023 in Review

Baillie Gifford & Co sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2023, closing a stake of 1,687 shares — an estimated $14.1K sold.

Baillie Gifford & Co first reported a position in BCRX in Q3 2021 and held it in 7 quarters. The position peaked at $27K in Q1 2022. 236 funds tracked by Wall St. Rank hold BCRX as of Q2 2023.

  • Baillie Gifford & Co reported no remaining BioCryst Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Baillie Gifford & Co sold 1,687 BioCryst Pharmaceuticals shares in Q2 2023, an estimated $14.1K.
  • Baillie Gifford & Co first reported a position in BioCryst Pharmaceuticals in Q3 2021 and held it in 7 quarters.
  • Baillie Gifford & Co's BioCryst Pharmaceuticals position peaked at $27K in Q1 2022.
  • 236 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2023.

Based on Baillie Gifford & Co's 13F filing for Q2 2023, filed 28 Jul 2023.